Lyme disease is an infectious disease caused by bacterial species borrelia. It is a tick borne disease caused by the transmission to humans by the bite of infected ticks. Patients infected with lyme disease suffer from symptoms such as fever, depression, fatigue and skin rashes. If the disease is diagnosed at an early stage then it can be treated with antibiotics. However, if the disease is left untreated then it affects heart, joint and central nervous system and might become a cause for death.
The lyme disease diagnostic market is segmented on the basis of diagnostic tests, emerging diagnostic technologies and end users. Emerging technologies segment comprises of molecular diagnostics, monoclonal antibodies, immunoassays, differential light scattering, liposomes, artificial intelligence, flow cytometry, information technology, diagnostic imaging, gel microdroplets, chromatography and others. The endusers segment of the market includes hospitals, commercial/private labs, public health labs and physicians office. Various forms of laboratory testing for lyme disease are available and among them most widely used are serological test. Among the serological tests most commonly used are ELISA and Western Blot. Moreover, some laboratories offer tests that include urine antigen tests, lymphocytic transformation test, immunofluorescent staining and PCR tests. New lyme disease diagnostic tests are being developed that are particularly suited for diagnosis of chronic lyme infection using blood sample. These tests overcome the accuracy problems which were encountered in serology based tests.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1658
Globally North America accounts for the largest share of the market owing to the most common tick disease in the U.S. According to the Center for Disease Control and Prevention (CDC) in 2011, 24,364 people were diagnosed with lyme disease in the United States. The European and Asian markets are also expected to emerge in near future owing to increase in patients infected with lyme diseases.
Some of the key players engaged in manufacturing of diagnostic tests include Abbott Laboratories, Affymetrix, Inc., Bio-Rad, Roche Diagnostics among others.
No comments:
Post a Comment